ArticleGenetics in medicine : official journal of the American College of Medical Genetics2026
A North Carolina newborn screening pilot for mucopolysaccharidosis II: Evaluating endogenous nonreducing end glycosaminoglycan analysis and IDS sequencing as higher-tier testing options.
Article in Genetics in medicine : official journal of the American College of Medical Genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
purposeMucopolysaccharidosis II (MPS II, OMIM 309900) is a lysosomal disorder recommended for newborn screening (NBS) in the United States. This study evaluated outcomes of high-throughput NBS for MPS II and use of 2 reflex testing methods to improve sensitivity and specificity.
methodsWe implemented a first-tier liquid chromatography tandem mass spectrometry laboratory-developed test measuring iduronate-2-sulfatase (I2S) enzyme activity in dried blood spots. Newborns with activity ≤10% of the daily median underwent reflex testing for endogenous nonreducing end (NRE) glycosaminoglycan (GAG) and IDS sequencing. Screen-positive infants were referred for clinical follow-up with urinary GAG testing and repeat dried blood spots I2S activity measurement.
resultsAmong approximately 220,000 newborns screened, 33 tested positive with low I2S activity. Two were confirmed with MPS II. Results of the remaining 31 newborns were indicative of pseudodeficiency. The NRE GAG ratios correlated with confirmatory urinary GAG measurements and were elevated exclusively in newborns with MPS II.
conclusionNBS for MPS II can be efficiently achieved with liquid chromatography tandem mass spectrometry measuring I2S activity. The NRE GAG biomarker successfully differentiated between newborns with MPS II and those with pseudodeficiency. Utilization of NRE GAG analysis as a 2nd-tier test significantly reduces the false-positive rate. IDS sequencing provides additional information for clinical evaluation and follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.